Diagnosed in more than 90% of cervical cancers, the fourth deadliest cancer in women,
human papillomavirus (HPV) is currently the most common pathogen responsible for female …

Introduction Human papillomavirus (HPV) infection, which poses significant disease burden,
is decreasing following implementation of vaccination programs. Synthesized evidence on …

Importance Cervical cancer is highly preventable but remains a common and deadly cancer
in areas without screening programs. The creation of a diagnostic system to digitize …

The long-term effect of population-level human papillomavirus (HPV) vaccination on the viral
ecology of the untargeted HPVs is poorly understood. We performed an 8-year follow-up of …

Background Major organizations recommend cytology screening (Pap test) every 3 years for
women aged 21–65; women aged 30 to 65 have the option of adding the HPV test (co-test) …

This review is based on the recent EUROGIN scientific session:“Assessing risk of cervical
cancer in the post‐vaccination era,” which addressed the demands of cervical intraepithelial …

Since being introduced in the 1940s, cervical cytology–despite its limitations–has had
unequivocal success in reducing cervical cancer burden in many countries. However, we …

Cervical cancer is the fourth most common cancer in women in the world. To eliminate
cervical cancer by 2030, the World Health Organization has given the target of 70 per cent …

Complete Round 1 data (baseline and 12‐month follow‐up) for HPV FOCAL, a randomized
trial establishing the efficacy of HPV DNA testing with cytology triage as a primary screen for …

Although human papillomavirus (HPV) vaccines offer enormous promise for the ultimate
control and possible elimination of cervical cancer, barriers to uptake and coverage of the …